Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?
Publication
, Conference
Gonzalez, R; Havrilesky, LJ; Secord, AA; Myers, ER; Dottino, JA; Moss, HA
Published in: Gynecologic Oncology
October 2020
Duke Scholars
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
October 2020
Volume
159
Start / End Page
21 / 22
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Gonzalez, R., Havrilesky, L. J., Secord, A. A., Myers, E. R., Dottino, J. A., & Moss, H. A. (2020). Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option? In Gynecologic Oncology (Vol. 159, pp. 21–22). Elsevier BV. https://doi.org/10.1016/j.ygyno.2020.06.043
Gonzalez, R., L. J. Havrilesky, A. A. Secord, E. R. Myers, J. A. Dottino, and H. A. Moss. “Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?” In Gynecologic Oncology, 159:21–22. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.043.
Gonzalez R, Havrilesky LJ, Secord AA, Myers ER, Dottino JA, Moss HA. Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option? In: Gynecologic Oncology. Elsevier BV; 2020. p. 21–2.
Gonzalez, R., et al. “Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?” Gynecologic Oncology, vol. 159, Elsevier BV, 2020, pp. 21–22. Crossref, doi:10.1016/j.ygyno.2020.06.043.
Gonzalez R, Havrilesky LJ, Secord AA, Myers ER, Dottino JA, Moss HA. Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option? Gynecologic Oncology. Elsevier BV; 2020. p. 21–22.
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
October 2020
Volume
159
Start / End Page
21 / 22
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis